The influenza sentinel surveillance in China was established in 2005 and has been substantially expanded from 193 to 554 sentinel hospitals since the 2009 influenza A(H1N1)pdm09 pandemic. The surveillance has involved multiple outpatient clinics in sentinel hospitals, including internal medicine, internal medicine emergency, pediatrics, pediatric emergency and fever clinics. The number of clinics would change over time because more sentinel hospitals have been included into the surveillance, and a small proportion of sentinel hospitals might have been removed from the surveillance system. The annual proportions of clinics involved in the surveillance are shown in Technical Appendix Table 1 .
network have been performing either virus culture followed by HAI assay or rRT-PCR or both for lineage determination.
Virus Culture Followed by HAI Assay
Samples are inoculated into MDCK (ATCC CCL 34) cells and/or specific pathogen-free embryonated chicken eggs (9-11 days old) for virus isolation in biosafety level 2 facilities at the influenza surveillance network laboratories. MDCK cells were grown in Dulbecco's modified Eagle's medium (Invitrogen,Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen). In the HAI assays, the standardized antigen and ferret antiserum that raised against B/Yamagata and B/Victoria lineages recommended by WHO for Northern Hemisphere influenza vaccine strains were prepared by the Chinese National Influenza Center (CNIC), one of WHO's influenza reference center, following the WHO Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (1). The standardized antigen and ferret antiserum were provided to all influenza surveillance network laboratories by CNIC. The details of virus culture followed by HAI assay to determine influenza B lineage have been published by the authors elsewhere (3). The quality control and assessment for the virus isolation and lineages differentiation were operated by CNIC yearly.
1-Step rRT-PCR for the Detection of Influenza B Lineage
Viral RNA was extracted using the QIAamp Viral RNA Minikit (QIAGEN, Hilden, Germany, cat.no. 52904) according to the manufacturer's instructions. One-step rRT-PCR was further used to detect influenza B type and determine lineages. The primers and probes sequence were provided by CNIC to all influenza surveillance network laboratories according to the WHO Information for the Molecular Detection of Influenza Viruses (2). The reaction master mixture and thermocycling conditions also was performed according to (2). A cycle threshold <37 was considered positive for the influenza B lineage determination. Several predominant influenza B virus strains, including B/Yamagata and B/Victoria in annual influenza epidemics, were used to validate the sensitivity of primers and probes. Several influenza A virus strains, including seasonal H1N1, pandemic H1N1, seasonal H3N2; and avian influenza H5N1, H9N2, and H7N9 (since 2013) were used to validate the specificity of the assays by CNIC yearly. The sequence of primers and probes with no cross-reactivity reactions would be provided to network laboratories for the lineage detection. All the 1-step rRT-PCRs were performed by network laboratories. The quality control and assessment for the lineages differentiation were operated by CNIC yearly. Table 2 reports the distributions of specimens by age group, province, and testing method in each year of the study period. *Seasons defined as the start of October until the end of September of the next year. The column sum of proportions by age group, province/municipality, PCR result, and testing method = 1. The distribution of positive specimens identified by PCR by laboratories that adopted the PCR approach or both PCR and HAI assay for virus identification is shown under "PCR result," in which A(others) showed the proportion of specimens with unsubtyped or co-infected seasonal influenza A viruses and avian influenza viruses including H5-positive, H7-positive, H9-positive; whereas B(others) showed the proportion of specimen with unsubtyped or co-infected influenza B viruses. HAI, hemagglutination-inhibition.
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